Business
Abbott develops medical devices, diagnostics, nutrition products and established pharmaceuticals.
Abbott: Revenue grew 5.7% to $44.328B from $41.95B. Net income declined 51.3% to $6.524B from $13.402B. Free cash flow grew 16.4% to $7.395B from $6.351B. Operating margin expanded 190 bps to 18.17%. Abbott's principal statistical and annual-change screens add no overriding warning to the reported profit and cash-flow record.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 5.7%OK
- Profitability — Net income declined 51.3% to $6.524B from $13.402BWatch
- Cash flow — Free cash flow grew 16.4% to $7.395B from $6.351BOK
- Margins — Operating margin expanded 190 bps to 18.17%OK
- Accounting — No overriding statistical warningNote
- Insiders — 5 purchases and 8 salesOK
Where the revenue comes from
Fiscal 2025, as ABBOTT LABORATORIES reports it. History and quarterly detail are in the app.
- Medical Devices$21.4B
- Diagnostics$8.9B
- Nutritionals$8.5B
- Established Pharmaceuticals$5.5B
Leadership changes
From ABBOTT LABORATORIES's own filings, the day they're filed.
- Kevin Conroy · Directors · appointmenteff. 2026-04-24
- Abbott Laboratories · Directors · appointmenteff. 2026-04-24
- Abbott Laboratories · Directors · appointmenteff. 2025-12-12
Latest filings
- 8-K · Company announcement2026-08-20
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-07-16
- 10-Q · Quarterly report2026-04-29
- 8-K · Company announcement2026-04-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ABBOTT LABORATORIES, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.